Biogen stock after-hours at EUR 200.20: minus 0.22 percent versus prior close

Biogen’s after-hours price was EUR 200.20 at 10:31 p.m. CEST on September 29, 2026, down 0.22 percent versus the Lang & Schwarz prior close. Recent updates covered LEQEMBI Pen and EMPAVELI.

Biogen stock was at EUR 200.20 after-hours at 10:31 p.m. CEST on September 29, 2026, down 0.22 percent versus the Lang & Schwarz prior close of EUR 200.65.

Recent company developments

In a September 16, 2026 release, Biogen and Eisai said Japan had approved LEQEMBI Pen, a subcutaneous formulation of lecanemab, as a new route of administration for early Alzheimer’s disease. The companies said the formulation uses two 250-milligram pens administered once weekly and can be administered by a care partner or patient after the applicable requirements are met.

Biogen reported on September 17, 2026, that a prespecified adolescent subgroup analysis from the Phase 3 VALIANT study had been published in the Clinical Journal of the American Society of Nephrology. Among 55 adolescents aged 12 to 17, EMPAVELI produced a 75 percent relative reduction in proteinuria versus placebo at Week 26, while 71 percent achieved at least a 50 percent reduction compared with 4 percent receiving placebo.

Next financial report

Biogen said on September 16, 2026, that it plans to report third-quarter 2026 financial results before the market opens on October 28, 2026. The company said a management webcast is scheduled for 8:30 a.m. Eastern Time.